Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Andrew McConaghie

Senior Writer

London, UK

Andrew writes on a range of topics across biopharma sector R&D and commercial issues, from new biotech start-ups to COVID-19 vaccines and new cancer, cell and gene therapies.

Latest From Andrew McConaghie

Corbus Keeps Rising On ADC And Obesity Plans

The company is on a roll thanks to its challenge to Pfizer’s Padcev and competition with a potential obesity market gamechanger from Novo Nordisk.

Clinical Trials Companies

Biotechs Vie To Take The Lead In Autoimmune CAR-Ts

First clinical efficacy readouts from several biotech companies developing CAR-Ts for systemic lupus erythematosus will be unveiled at EULAR, though the level of competition may be unsustainable.

Clinical Trials Companies

Skye Bioscience Looks To Build Appetite For CB1 Obesity Drug

The company will take on Novo Nordisk in reviving the CB1 inhibitor mechanism to develop a more tolerable long-term weight loss drug, after exiting ophthalmology.

Companies Clinical Trials

EASL: Sagimet Pill Is Overlooked But Could Make A Splash In MASH

While injectables have had all the limelight, some analysts see a bright future for Sagimet’s oral denifanstat, potentially as a backbone therapy in combination with other treatments for MASH.

Clinical Trials Liver & Hepatic

Boehringer Backs Up Best-In-Class MASH Claims With Fibrosis Data

Survodutide burnishes its best-in-class MASH case with a 64% improvement in moderate-to advanced fibrosis at Phase II, but tolerability an issue

Clinical Trials Metabolic Disorders

ASCO: AstraZeneca Achieves Eye-Catching Solid Tumor Results With 'Armored' CAR-T

Solid tumor CAR-T may succeed AZD7003 where many others have failed as the firm builds its cell therapy pipeline.

Clinical Trials Companies
See All
UsernamePublicRestriction

Register